2019-10-10 |
101 |
Opinion |
assignee of U.S. Patent Nos. 8,217,078
(“the ’078 patent”); 9,132,110 (“the ’110 patent”); 8,618,164
(…Drug Application No. 204623 and of U.S. Patent
Nos. 8,217,078; 8,252,838; 8,546,450; 8,563,613; 9,066,913… (“the ’164 patent”); 9,168,304 (“the ’304 patent”); 9,168,305
(“the ’305 patent”); 8,546,450 (“the ’… ’450 patent”); 9,101,591
(“the ’591 patent”); 8,563,613 (“the ’613 patent”); 9,220,784
(“the ’784 patent… patent”); 8,871,809 (“the ’809 patent”); 8,252,838
(“the ’838 patent”); and 9,066,913 (“the ’913 patent |
External link to document |
2016-08-17 |
64 |
|
related to U.S. Patent Nos. 9,168,304 (“the ’304
patent”), 9,168,305 (“the ’305 patent”), and 9,220,784…that in patent construction, subsidiary factfinding is sometimes
necessary.”). A patent claim is…Camera
Patent Litigation, 778 F.3d 1255, 1261 (Fed. Cir. 2015). In
construing a patent claim…construction is the
language of the patent. Claim 12 of the ’304 patent claims,
“The topical formulation…Chicago, Illinois 60611
Dennis A. Bennett
GLOBAL PATENT GROUP, LLC
1005 North Warson Road, Suite 404
|
External link to document |